Research.Patient.info
Thrombocytopenia, Neonatal Alloimmune research hub
2 indexed studies · 2 currently recruiting
- recruitingPHASE3
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
This study is looking at new ways to prevent a serious bleeding condition in babies called FNAIT. It compares a new medicine, nipocalimab, with standard treatments like IVIG, in pregnant women who have had FNAIT before. The aim is to find safer, more effective ways to protect newborns.
United States · Austria · Germany - recruitingPHASE3
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
This study is testing a new medicine, nipocalimab, to see if it can help prevent a serious blood condition called FNAIT in babies. FNAIT can cause low platelet counts in newborns, which can lead to bleeding problems. Researchers want to know if nipocalimab is effective and safe.
Belgium · Brazil · France